Gray market peptides column cites ER survey it does not name

WESTFIELD, MASS. A nurse practitioner with about four decades in emergency care has warned readers that gray market peptides carry real harm and no proven benefit. Her opinion column, published November 6 in the Westfield Health Bulletin on MassLive, says 3 in 10 of 1,000 surveyed peptide users went to an emergency room, but it does not name the survey. The piece also attacks a federal policy that opened pharmacy compounding to six unapproved peptides. Peptide Zone reviewed which of its claims carry a source and which do not.

What the Westfield column says

Juanita Carnes, who served 30 years on the Westfield Board of Health, wrote the piece for the town's health bulletin. In her MassLive column, she describes gray market peptides as imported products sold outside the regulated pharmacy system. She says most come from China and are promoted on social media and sold online and through some spas, wellness clinics and virtual health companies. The marketing claims she lists include skin renewal, tendon repair, faster surgical recovery, better sleep and more muscle. She singles out products sold as the "Wolverine Stack," named after the comic book hero with a healing power. The column says these sellers will pass $100 million in profits this year. It gives no source for that figure.

Carnes draws a line between these products and approved peptide medicines. She names insulin, GLP 1 drugs for diabetes and weight loss, and Pitocin, used to speed labor, as synthetic peptides that went through FDA review and remain under safety monitoring after approval. By contrast, she writes, many gray market peptides are labeled for research only and not for human use. She warns that contents may differ from the label and may include heavy metals, and that no one checks for bacterial contamination. Buyers often draw from multi dose vials themselves, which she links to dosing errors and overdoses. She adds that skipping pharmacists and prescribers removes screening for drug interactions, advice on side effects and help when complications appear.

Survey of peptide emergency room visits lacks a named source

The most striking number in the column is a survey figure. Carnes writes that among 1,000 peptide users surveyed, 3 in 10 visited an emergency room because of their peptide use. The column does not name the survey, its authors, its date, how people were recruited or which peptides they used. Peptide Zone could not identify the study behind the figure before publication. Without those details, readers cannot judge whether the sample reflects typical users, whether visits were confirmed by records, or whether GLP 1 drugs were counted alongside unapproved compounds. That last point matters for any tally of peptide emergency room visits, because an emergency physician told OMED that GLP 1 drugs drive most peptide visits.

The column does not name the survey, its authors, its date, how people were recruited or which peptides they used.

Carnes also quotes Christopher Robinson, a physician scientist at Johns Hopkins, on why personal success stories are weak evidence. An injury may heal on its own, with rest or through the placebo effect, she writes. Robinson says the only way to know for sure is "to test it in well-designed clinical trials with a large enough group of people to distinguish a true treatment effect from an expectation, a coincidence or the body's natural healing mechanisms." The column says he is seeking federal funding to study peptides. "There's real potential here, but potential isn't the same as proof," Robinson said, according to the column. The column does not say where or when he made these remarks.

Peptide side effects listed without links to specific compounds

The column lists a long set of peptide side effects. They include immune reactions, anaphylaxis, motor paralysis, skeletal muscle damage, diabetes, hypothyroidism, high blood pressure, blood clots, osteoporosis, liver and pancreas problems and cancer. Skin abscesses, fluid retention, congestive heart failure and gut symptoms such as nausea, vomiting and diarrhea also appear. The list is not tied to any one product. Peptides differ widely in what they do in the body, and the column does not say which compound was linked to which harm, or whether each effect came from human reports, animal work or theory. The list is best read as possible risks spread across many substances, not as the known profile of any single vial sold online.

Some risks are on the record with regulators. The FDA keeps a list of bulk substances that raise safety concerns in compounding, and this site has reported that its entries cite deaths in studies of GHRP 2 and ipamorelin, without proven cause. The same FDA page flags thin safety data for BPC 157 and five other peptides now covered by federal policy. Contamination is a separate risk from the molecule itself. Customs tests in Iceland found many seized peptide vials did not contain what their labels claimed, which fits the column's warning about mislabeled contents. The table below sorts the column's main claims by whether it names a source.

Federal policy on six unapproved peptides and what comes next

Carnes saves her sharpest words for federal health officials. She writes that the HHS secretary has described his own success with peptides and announced that six unapproved peptides would be made available, including a "Wolverine Blend." She reads this as a signal that laws protecting the public need not be enforced, and she invokes thalidomide. Peptide Zone has reported that the interim HHS peptide compounding policy lets licensed pharmacies compound BPC 157, epitalon, KPV, MOTS c, Semax and TB 500 under ten conditions. None of the six is FDA approved, and FDA reviewers advised against listing them. Compounding by a licensed pharmacy is not the same as buying a research vial online, though the column criticizes both routes.

The policy is interim, and a final rule is still pending. Public comments close November 13, according to earlier reporting on this site. Pharmacists have argued the policy offers a safer route than gray market peptides, while pharmacologists counter that none of the six has passed FDA testing. For people weighing these products, the legitimate options remain approved peptide medicines prescribed by a clinician and dispensed by a pharmacy, or enrollment in a registered clinical trial. Anyone who has a reaction after injecting an unapproved product should seek medical care and can report it to the FDA MedWatch program. This report is for news and research purposes only and is not medical advice.

Conclusion

The Westfield column adds an emergency clinician's voice to warnings about gray market peptides, but its central number rests on a survey it does not identify. Its broader points match what regulators and researchers have said: unapproved products lack trial evidence, contents can differ from labels, and buyers lose the checks a pharmacy provides. Next comes the end of the comment period on November 13 and any final federal rule. Until larger trials report, claims of benefit for these peptides remain unproven.